![Western Blot: ELF3/ESE-1 Antibody [NBP1-30873] - Loss of Elf3 preserves the mesenchymal state. Immunoblot showing ELF3 and E-cadherin protein levels in response to Elf3 silencing by siRNAs. Image collected and cropped by CiteAb from the following publication (//www.mdpi.com/2073-4409/8/8/858) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/ELF3-ESE-1-Antibody-Western-Blot-NBP1-30873-img0010.jpg "Western Blot: ELF3/ESE-1 Antibody [NBP1-30873] - Loss of Elf3 preserves the mesenchymal state. Immunoblot showing ELF3 and E-cadherin protein levels in response to Elf3 silencing by siRNAs. Image collected and cropped by CiteAb from the following publication (//www.mdpi.com/2073-4409/8/8/858) licensed under a CC-BY license.")
| Reactivity | Hu, Mu, RtSpecies Glossary |
| Applications | WB, ICC/IF, IHC, ChIP |
| Clonality | Polyclonal |
| Host | Rabbit |
| Conjugate | Unconjugated |
| Immunogen | Carrier-protein conjugated synthetic peptide encompassing a sequence within the C-terminus region of human ELF3/ESE-1. The exact sequence is proprietary. |
| Localization | Cytoplasm, Nucleus |
| Isotype | IgG |
| Clonality | Polyclonal |
| Host | Rabbit |
| Gene | ELF3 |
| Purity | Antigen Affinity-purified |
| Innovator's Reward | Test in a species/application not listed above to receive a full credit towards a future purchase. |
| Dilutions |
|
|
| Theoretical MW | 41 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors. |
|
| Publications |
|
| Storage | Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles. |
| Buffer | PBS, 20% Glycerol |
| Preservative | 0.01% Thimerosal |
| Purity | Antigen Affinity-purified |
![Western Blot Ets-1 Antibody [Unconjugated]](https://images.novusbio.com/images2/Ets-1_AF7284_Western_Blot_11854.jpg)
![Immunohistochemistry Ets-1 Antibody [Unconjugated]](https://images.novusbio.com/images2/Ets1_AF7284_Immunohistochemistry_22698.jpg)
![Immunohistochemistry ACE/CD143 Antibody [Unconjugated]](https://images.novusbio.com/images2/ACE_AF1513_Immunohistochemistry_6703.jpg)
![Western Blot ACE/CD143 Antibody [Unconjugated]](https://images.novusbio.com/images2/ACE_AF1513_Flow_Cytometry_20028.jpg)
![Simple Western ACE/CD143 Antibody [Unconjugated]](https://images.novusbio.com/images2/ACE_AF1513_Simple_Western_20109.jpg)
Secondary Antibodies |
Isotype Controls |
Research Areas for ELF3/ESE-1 Antibody (NBP1-30873)Find related products by research area.
|
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
| Gene Symbol | ELF3 |
![Immunocytochemistry/Immunofluorescence: ELF3/ESE-1 Antibody [NBP1-30873] - Methanol-fixed HeLa, using antibody at 1:500 dilution.](http://images.novusbio.com/fullsize/ELF3-ESE-1-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-30873-img0006.jpg "Immunocytochemistry/Immunofluorescence: ELF3/ESE-1 Antibody [NBP1-30873] - Methanol-fixed HeLa, using antibody at 1:500 dilution.")
![Immunohistochemistry-Paraffin: ELF3/ESE-1 Antibody [NBP1-30873] - Human lung carcinoma. ESE1 antibody [C2C3], C-term diluted at 1:500. Antigen Retrieval: Trilogy™ (EDTA based, pH 8.0) buffer, 15min.](http://images.novusbio.com/fullsize/ELF3-ESE-1-Antibody-Immunohistochemistry-Paraffin-NBP1-30873-img0009.jpg "Immunohistochemistry-Paraffin: ELF3/ESE-1 Antibody [NBP1-30873] - Human lung carcinoma. ESE1 antibody [C2C3], C-term diluted at 1:500. Antigen Retrieval: Trilogy™ (EDTA based, pH 8.0) buffer, 15min.")
![Immunohistochemistry-Paraffin: ELF3/ESE-1 Antibody [NBP1-30873] - NCI-N87 xenograft, using ESE1 antibody at 1:100 dilution. Antigen Retrieval: Trilogy™ (EDTA based, pH 8.0) buffer, 15min.](http://images.novusbio.com/fullsize/ELF3-ESE-1-Antibody-Immunohistochemistry-Paraffin-NBP1-30873-img0007.jpg "Immunohistochemistry-Paraffin: ELF3/ESE-1 Antibody [NBP1-30873] - NCI-N87 xenograft, using ESE1 antibody at 1:100 dilution. Antigen Retrieval: Trilogy™ (EDTA based, pH 8.0) buffer, 15min.")
![Chromatin Immunoprecipitation: ELF3/ESE-1 Antibody [NBP1-30873] - The transcription factor ELF3 regulates the Grhl3 promoter. (A) The sequence of the Grhl3 promoter (1000 bp) showing the location of the predicted TATA box, SP1 sequence, & the transcription start site. Sequences in red represent the conserved regions, & green bases represent putative ELF3 binding sites. (B) Luciferase reporter assay showing the activation of the Grhl3 promoter by ELF3. Relative luciferase activity is calculated as fold induction relative to vector. Drawings on the left side show a schematic representation of the Grhl3 promoter region (top) & the structure of each reporter plasmid (below). The conserved regions are shown as horizontal boxes labeled 1,2 & 3, the restriction enzymes used to generate the reporter deletions of the promoter are labeled. (C) ELF3 binding at the promoter of Grhl3. NMuMG cells were treated with either vehicle or TGF beta 3 for 72 h, TGF beta 3 treated cells were then washed with PBS & continued incubation for an additional 48 h to initiate MET (post-treatment: PT48). Cells were cross-linked, & chromatin immunoprecipitation was performed. ChIP DNA was used in qPCR to measure the occupancy of ELF3 compared to control antibodies. (D) Sequence alignment of one putative ELF3 binding site in the Grhl3 promoter showing conservation among different species. In B & C, data represent the averages of at least three independent experiments. The paired Student’s t-test was used to calculate statistical significance. ** p-value < 0.01; **** p-value < 0.0001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31404945), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-30873_rabbit-polyclonal-elf3-ese-1-antibody-310202416182629.jpg "Chromatin Immunoprecipitation: ELF3/ESE-1 Antibody [NBP1-30873] - The transcription factor ELF3 regulates the Grhl3 promoter. (A) The sequence of the Grhl3 promoter (1000 bp) showing the location of the predicted TATA box, SP1 sequence, & the transcription start site. Sequences in red represent the conserved regions, & green bases represent putative ELF3 binding sites. (B) Luciferase reporter assay showing the activation of the Grhl3 promoter by ELF3. Relative luciferase activity is calculated as fold induction relative to vector. Drawings on the left side show a schematic representation of the Grhl3 promoter region (top) & the structure of each reporter plasmid (below). The conserved regions are shown as horizontal boxes labeled 1,2 & 3, the restriction enzymes used to generate the reporter deletions of the promoter are labeled. (C) ELF3 binding at the promoter of Grhl3. NMuMG cells were treated with either vehicle or TGF beta 3 for 72 h, TGF beta 3 treated cells were then washed with PBS & continued incubation for an additional 48 h to initiate MET (post-treatment: PT48). Cells were cross-linked, & chromatin immunoprecipitation was performed. ChIP DNA was used in qPCR to measure the occupancy of ELF3 compared to control antibodies. (D) Sequence alignment of one putative ELF3 binding site in the Grhl3 promoter showing conservation among different species. In B & C, data represent the averages of at least three independent experiments. The paired Student’s t-test was used to calculate statistical significance. ** p-value < 0.01; **** p-value < 0.0001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31404945), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![Western Blot: ELF3/ESE-1 Antibody [NBP1-30873] - Various whole cell extracts (30 ug) were separated by 10% SDS-PAGE, and the membrane was blotted with ESE1 antibody [C2C3], C-term diluted at 1:1000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody. Corresponding RNA expression data for the same cell lines are based on Human Protein Atlas program.](http://images.novusbio.com/fullsize/nbp1-30873_rabbit-polyclonal-elf3-ese-1-antibody-161020241941455.jpg "Western Blot: ELF3/ESE-1 Antibody [NBP1-30873] - Various whole cell extracts (30 ug) were separated by 10% SDS-PAGE, and the membrane was blotted with ESE1 antibody [C2C3], C-term diluted at 1:1000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody. Corresponding RNA expression data for the same cell lines are based on Human Protein Atlas program.")
![Enzyme Activity alpha-Galactosidase A/GLA [Unconjugated]](https://images.novusbio.com/images2/6146-gh_recombinant-human-alpha-galactosidase-a-gla-protein-cf-enzyme-activity-322023131935.jpg)
![Enzyme Activity alpha-Galactosidase A/GLA [Unconjugated]](https://images.novusbio.com/images2/6146-gh_recombinant-human-alpha-galactosidase-a-gla-protein-cf-enzyme-activity-32202314939.jpg)
![SDS-PAGE alpha-Galactosidase A/GLA [Unconjugated]](https://images.novusbio.com/images2/6146-gh_recombinant-human-alpha-galactosidase-a-gla-protein-cf-sds-page-322023141819.jpg)
![Simple Western Glucosylceramidase/GBA Antibody (812201) [Unconjugated]](https://images.novusbio.com/images2/16239.jpg)
![Western Blot Glucosylceramidase/GBA Antibody (812201) [Unconjugated]](https://images.novusbio.com/images2/Glucosylceramidase_MAB7410_Western_Blot_12708.jpg)
![Immunocytochemistry Glucosylceramidase/GBA Antibody (812201) [Unconjugated]](https://images.novusbio.com/images2/Glucosylceramidase_MAB7410_Immunocytochemistry_12732.jpg)
![Western Blot c-jun [p Ser63] Antibody (1018Y) [Unconjugated]](https://images.novusbio.com/images2/cJun_MAB8930_Western_Blot_18923.jpg)
![Immunocytochemistry c-jun [p Ser63] Antibody (1018Y) [Unconjugated]](https://images.novusbio.com/images2/cJun_MAB8930_Immunocytochemistry__Immunofluorescence_18945.jpg)
![Simple Western c-jun [p Ser63] Antibody (1018Y) [Unconjugated]](https://images.novusbio.com/images2/cJun_MAB8930_Simple_Western_19175.jpg)
![N/A IL-6 [HRP]](https://images.novusbio.com/images2/DATA_IL6_M6000_ELISA_936.jpg)
![N/A IL-6 [HRP]](https://images.novusbio.com/images2/IL-6_M6000_ELISA_415.jpg)
![N/A IL-6 [HRP]](https://images.novusbio.com/images/m6000b_mouse-il-6-quantikine-elisa-kit-44202415433118.jpg)
![SDS-PAGE IGF-I/IGF-1 [Unconjugated]](https://images.novusbio.com/images2/IGF-I_291-G1_40.jpg)
![Bioactivity IGF-I/IGF-1 [Unconjugated]](https://images.novusbio.com/images2/IGF-I_291-G1_41.jpg)
![Mass Spectrometry IGF-I/IGF-1 [Unconjugated]](https://images.novusbio.com/images2/IGF-I_291-G1_42.jpg)
![SDS-PAGE TNF-alpha [Unconjugated]](https://images.novusbio.com/images2/TNF-alpha_210-TA_256.jpg)
![Bioactivity TNF-alpha [Unconjugated]](https://images.novusbio.com/images2/TNFalpha_210TA_1658.jpg)
![SEC-MALS TNF-alpha [Unconjugated]](https://images.novusbio.com/images/210-ta_recombinant-human-tnf-alpha-protein-sec-mals-35202312244..jpg)
![SDS-PAGE LIGHT/TNFSF14 [Unconjugated]](https://images.novusbio.com/images2/LIGHT_664-LI_719.jpg)
![Bioactivity LIGHT/TNFSF14 [Unconjugated]](https://images.novusbio.com/images2/LIGHT_664-LI_721.jpg)
![Western Blot Catalase Antibody [Unconjugated]](https://images.novusbio.com/images2/Catalase_AF3398_Western_Blot_5287.jpg)
![Simple Western Catalase Antibody [Unconjugated]](https://images.novusbio.com/images2/Catalase_AF3398_Simple_Western_16990.jpg)
![Knockout Validated Catalase Antibody [Unconjugated]](https://images.novusbio.com/images2/Catalase_AF3398_Knockout_Validated_24032.jpg)
![SDS-PAGE ErbB2/Her2 [Unconjugated]](https://images.novusbio.com/images2/ErbB2_1129-ER_70.jpg)
![Bioactivity ErbB2/Her2 [Unconjugated]](https://images.novusbio.com/images2/1129-er_recombinant-human-erbb2-her2-fc-chimera-protein-cf-bioactivity-7122020142841.jpg)
![Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP] [NB7160] - Western blot showing vemurafenib treatment in BRAFV600E CRC cells inhibits fission mediator DRP1 with no significant effect on fusion proteins (Mfn1 & 2) using MFN-1 antibody (NBP1-51841) and corresponding secondary antibody, goat anti-rabbit IgG-HRP (NB7160). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33738242).](https://images.novusbio.com/images/Goat-anti-Rabbit-IgG-H+L-Secondary-Antibody-HRP-Western-Blot-NB7160-img0001.jpg "Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP] [NB7160] - Western blot showing vemurafenib treatment in BRAFV600E CRC cells inhibits fission mediator DRP1 with no significant effect on fusion proteins (Mfn1 & 2) using MFN-1 antibody (NBP1-51841) and corresponding secondary antibody, goat anti-rabbit IgG-HRP (NB7160). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33738242).")
![Flow Cytometry: Rabbit IgG Isotype Control [NBP2-24891] - Intracellular FACS analysis of mouse TLR6 polyclonal antibody (red), rabbit isotype control (green), RAW cells alone (shaded). Two micrograms of antibodies were used. Goat anti-rabbit FITC (Novus, 20302) was used as secondary.](https://images.novusbio.com/images/Rabbit--Mouse-IgG-Isotype-Control-Flow-Cytometry-NBP2-24891-img0001.jpg "Flow Cytometry: Rabbit IgG Isotype Control [NBP2-24891] - Intracellular FACS analysis of mouse TLR6 polyclonal antibody (red), rabbit isotype control (green), RAW cells alone (shaded). Two micrograms of antibodies were used. Goat anti-rabbit FITC (Novus, 20302) was used as secondary.")